Literature DB >> 33392213

Clinical Characteristics and Neonatal Outcomes of Pregnant Patients With COVID-19: A Systematic Review.

Md Mohaimenul Islam1,2,3, Tahmina Nasrin Poly1,2,3, Bruno Andreas Walther4, Hsuan Chia Yang1,2,3, Cheng-Wei Wang5, Wen-Shyang Hsieh6,7, Suleman Atique8, Hosna Salmani9, Belal Alsinglawi10, Ming Ching Lin1,11,12,13,14, Wen Shan Jian15, Yu-Chuan Jack Li1,2,3,16,17.   

Abstract

Background and Objective: Coronavirus disease 2019 (COVID-19) characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created serious concerns about its potential adverse effects. There are limited data on clinical, radiological, and neonatal outcomes of pregnant women with COVID-19 pneumonia. This study aimed to assess clinical manifestations and neonatal outcomes of pregnant women with COVID-19.
Methods: We conducted a systematic article search of PubMed, EMBASE, Scopus, Google Scholar, and Web of Science for studies that discussed pregnant patients with confirmed COVID-19 between January 1, 2020, and April 20, 2020, with no restriction on language. Articles were independently evaluated by two expert authors. We included all retrospective studies that reported the clinical features and outcomes of pregnant patients with COVID-19.
Results: Forty-seven articles were assessed for eligibility; 13 articles met the inclusion criteria for the systematic review. Data is reported for 235 pregnant women with COVID-19. The age range of patients was 25-40 years, and the gestational age ranged from 8 to 40 weeks plus 6 days. Clinical characteristics were fever [138/235 (58.72%)], cough [111/235 (47.23%)], and sore throat [21/235 (8.93%)]. One hundred fifty six out of 235 (66.38%) pregnant women had cesarean section, and 79 (33.62%) had a vaginal delivery. All the patients showed lung abnormalities in CT scan images, and none of the patients died. Neutrophil cell count, C-reactive protein (CRP) concentration, ALT, and AST were increased but lymphocyte count and albumin levels were decreased. Amniotic fluid, neonatal throat swab, and breastmilk samples were taken to test for SARS-CoV-2 but all found negativ results. Recent published evidence showed the possibility of vertical transmission up to 30%, and neonatal death up to 2.5%. Pre-eclampsia, fetal distress, PROM, pre-mature delivery were the major complications of pregnant women with COVID-19. Conclusions: Our study findings show that the clinical, laboratory and radiological characteristics of pregnant women with COVID-19 were similar to those of the general populations. The possibility of vertical transmission cannot be ignored but C-section should not be routinely recommended anymore according to latest evidences and, in any case, decisions should be taken after proper discussion with the family. Future studies are needed to confirm or refute these findings with a larger number of sample sizes and a long-term follow-up period.
Copyright © 2020 Islam, Poly, Walther, Yang, Wang, Hsieh, Atique, Salmani, Alsinglawi, Lin, Jian and Jack Li.

Entities:  

Keywords:  COVID-19; CT-scan; SARS–CoV-2; coronavirus; pregnant women

Year:  2020        PMID: 33392213      PMCID: PMC7772992          DOI: 10.3389/fmed.2020.573468

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  10 in total

1.  COVID-19 and the neonatal microbiome: will the pandemic cost infants their microbes?

Authors:  Joann Romano-Keeler; Jilei Zhang; Jun Sun
Journal:  Gut Microbes       Date:  2021 Jan-Dec

Review 2.  Systematic review and meta-analysis of COVID-19 maternal and neonatal clinical features and pregnancy outcomes up to June 3, 2021.

Authors:  Greg Marchand; Avinash S Patil; Ahmed T Masoud; Kelly Ware; Alexa King; Stacy Ruther; Giovanna Brazil; Nicolas Calteux; Hollie Ulibarri; Julia Parise; Amanda Arroyo; Catherine Coriell; Chelsea Cook; Alexandra Ruuska; Anas Zakarya Nourelden; Katelyn Sainz
Journal:  AJOG Glob Rep       Date:  2022-01-03

Review 3.  The Effects of COVID-19 on the Placenta During Pregnancy.

Authors:  Habib Sadeghi Rad; Joan Röhl; Nataly Stylianou; Mark C Allenby; Sajad Razavi Bazaz; Majid E Warkiani; Fernando S F Guimaraes; Vicki L Clifton; Arutha Kulasinghe
Journal:  Front Immunol       Date:  2021-09-15       Impact factor: 8.786

4.  Management of severe neonatal respiratory distress due to vertical transmission of severe acute respiratory syndrome coronavirus 2: a case report.

Authors:  Anne C Verheijen; Eva E R Janssen; Mayke E van der Putten; Marieke W P van Horck; Gijs T J van Well; Inge H M Van Loo; Matthias C Hütten; Karen Van Mechelen
Journal:  J Med Case Rep       Date:  2022-03-28

5.  Are in-hospital COVID-19-related mortality and morbidity in pregnancy associated with gestational age?

Authors:  C Leung; A C Simões E Silva; E A Oliveira
Journal:  Ultrasound Obstet Gynecol       Date:  2022-08       Impact factor: 8.678

6.  Better healthcare can reduce the risk of COVID-19 in-hospital post-partum maternal death: evidence from Brazil.

Authors:  Char Leung; Li Su; Ana Cristina Simões E Silva
Journal:  Int J Epidemiol       Date:  2022-08-10       Impact factor: 9.685

7.  Maternal and Perinatal Outcomes of COVID-19-Positive Pregnant Women.

Authors:  Pragya Shree; Nupur Mittal; Soniya Vishwakarma; Vandana Verma; Virendra Pandey; Ekta Thadani
Journal:  Cureus       Date:  2022-06-28

8.  Excretion of SARS-CoV-2 in breast milk: a single-centre observational study.

Authors:  Arun Prasad; Yankappa N; Pradeep Kumar; Bhavesh Kant Chaudhary; Binod Kumar Pati; Monika Anant; Lokesh Kumar Tiwari
Journal:  BMJ Paediatr Open       Date:  2021-06-02

Review 9.  Covid-19 imaging: A narrative review.

Authors:  Hanae Ramdani; Nazik Allali; Latifa Chat; Siham El Haddad
Journal:  Ann Med Surg (Lond)       Date:  2021-06-18

10.  Is SARS-CoV-2 Infection a Risk Factor for Early Pregnancy Loss? ACE2 and TMPRSS2 Coexpression and Persistent Replicative Infection in Primitive Trophoblast.

Authors:  Jie Zhou; Sehee Choi; Heidi Liu; Jialin Zhang; Yuchen Tian; Andrea G Edlow; Toshihiko Ezashi; R Michael Roberts; Wenjun Ma; Danny J Schust
Journal:  J Infect Dis       Date:  2021-12-08       Impact factor: 7.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.